TrialJournal of Crohn's & colitis2026

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.